Amplia Therapeutics has filed a patent for a method of treating or preventing pulmonary fibrosis by administering a FAK inhibitor to patients in need. The patent claims that the FAK inhibitor, defined by formula I or its derivative, can effectively treat or prevent pulmonary fibrosis. GlobalData’s report on Amplia Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Amplia Therapeutics, cancer treatment biomarkers was a key innovation area identified from patents. Amplia Therapeutics's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Treating or preventing pulmonary fibrosis using a fak inhibitor
A recently filed patent (Publication Number: US20230190746A1) describes a method for treating or preventing pulmonary fibrosis in patients. The method involves administering a FAK inhibitor, specifically one defined by formula I or a pharmaceutically acceptable derivative thereof, to the patient. Pulmonary fibrosis is a condition characterized by the scarring and thickening of lung tissue, leading to difficulty in breathing and reduced lung function.
In claim 4 of the patent, it is specified that the FAK inhibitor can be administered in the form of a tartrate salt. Tartrate salts are commonly used in pharmaceutical formulations to enhance the stability and solubility of drugs. This claim suggests that the use of a tartrate salt as a delivery form for the FAK inhibitor may be advantageous in the treatment or prevention of pulmonary fibrosis.
Claim 5 of the patent highlights that the method is particularly applicable to patients with idiopathic pulmonary fibrosis (IPF). IPF is a specific type of pulmonary fibrosis where the cause is unknown. By targeting this specific condition, the method described in the patent may offer a targeted approach to treating or preventing IPF.
Furthermore, claim 6 of the patent suggests that the method can also be effective in treating or preventing pulmonary fibrosis associated with infection with a coronavirus. This claim is particularly relevant in the current context of the COVID-19 pandemic, as some patients who have recovered from COVID-19 have experienced pulmonary fibrosis as a long-term consequence of the infection. The use of a FAK inhibitor as described in the patent may provide a potential therapeutic option for these patients.
In summary, the filed patent describes a method for treating or preventing pulmonary fibrosis by administering a FAK inhibitor to patients. The method may be particularly beneficial for patients with idiopathic pulmonary fibrosis or those with pulmonary fibrosis associated with coronavirus infection. The use of a tartrate salt as a delivery form for the FAK inhibitor is also mentioned in the patent. This patent may contribute to the development of new treatment options for pulmonary fibrosis, a condition that currently has limited therapeutic options.
To know more about GlobalData’s detailed insights on Amplia Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
